Clolar receives FDA approval

On December 28 , 2004, the U. S. Food and Drug Administration (FDA) granted marketing approval for clofarabine (Clolar) for treatment of pediatric patients 1 to 21 years old with acute lymphoblastic leukemia. Approval was granted under accelerated approval regulations that require the sponsor to conduct and complete additional clinical studies to confirm clinical benefit. Clolar was developed by Ilex Oncology, Inc.